Jonathan Dennis Email Address

Senior Training Manager, Alzheimer's Eisai US

AVANIR Pharmaceuticals (AVANIR) is a pharmaceutical company focused on developing, acquiring and commercializing therapeutic products for the treatment of chronic diseases. The Companys product candidates address therapeutic markets that include the central nervous system, inflammatory diseases and infectious diseases. Its principal product candidate, Zenviatm (dextromethorphan hydrobromide/quinidine sulfate), is in Phase III clinical development for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). AVANIRs first commercialized product, docosanol 10% cream, (sold as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare in North America) is an over-the-counter treatment for cold sores that has been approved by the United States Food and Drug Administration (FDA). AVANIR entered into an agreement in July 2007, to sell FazaClo to Azur Pharma, Inc. (Azur). The sale was closed on August 3, 2007.

Extensive experience in Bio/Pharma/Medical Sales with an award winning proven track record in new product launches, business analytics, managed markets, strategy, goal attainment and training. Exceedingly successful at developing people, motivating others, implementing change initiatives and leading change. Trusted advisor throughout the organization. Committed to delivering high quality results, overcoming challenges, and focusing on what matters, execution. Extensive experience building strong relationships and collaboration, managing trusted stakeholder relationships both internal and external. Highly organized, strategic thinker with excellent verbal, written, and presentation communication skills.